会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明申请
    • Method of treating dry eye disease with purinergic receptor agonists
    • 用嘌呤能受体激动剂治疗干眼病的方法
    • US20080009463A1
    • 2008-01-10
    • US11821091
    • 2007-06-20
    • Benjamin YerxaKarla JacobusWilliam PendergastJanet Rideout
    • Benjamin YerxaKarla JacobusWilliam PendergastJanet Rideout
    • A61K31/7084A61P27/02
    • C07H19/10A61K9/0048A61K31/7084A61K45/06C07H19/20C07H21/00Y10S514/912Y10S514/915
    • A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.
    • 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。
    • 14. 发明授权
    • Method of treating dry eye disease with purinergic receptor agonists
    • 用嘌呤能受体激动剂治疗干眼病的方法
    • US06921755B2
    • 2005-07-26
    • US10010055
    • 2001-11-09
    • Benjamin R. YerxaKarla M. JacobusWilliam PendergastJanet L. Rideout
    • Benjamin R. YerxaKarla M. JacobusWilliam PendergastJanet L. Rideout
    • A61K45/06A61K31/70
    • A61K45/06Y10S514/912
    • A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.
    • 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。
    • 18. 发明授权
    • Method of treating dry eye disease with purinergic receptor agonists
    • 用嘌呤能受体激动剂治疗干眼病的方法
    • US07759322B2
    • 2010-07-20
    • US11821091
    • 2007-06-20
    • Benjamin R. YerxaKarla M. JacobusWilliam PendergastJanet L. Rideout
    • Benjamin R. YerxaKarla M. JacobusWilliam PendergastJanet L. Rideout
    • A01N43/04A61K31/70
    • C07H19/10A61K9/0048A61K31/7084A61K45/06C07H19/20C07H21/00Y10S514/912Y10S514/915
    • A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.
    • 公开了用于刺激需要这种治疗的受试者的泪液分泌的方法和制剂。 该方法包括向受试者的眼表面施用嘌呤能受体激动剂如尿苷5'-三磷酸(UTP),二核苷酸,胞苷5'-三磷酸(CTP),腺苷5'-三磷酸(ATP)或其治疗上有用的 类似物和衍生物,其量有效地刺激泪液分泌并增强泪液系统的引流。 还公开了药物制剂及其制备方法。 施用该方法的方法将包括:通过液体,凝胶,霜剂或作为隐形眼镜或选择性释放膜的一部分局部给药; 或通过鼻滴或喷雾进行全身给药,通过喷雾器或其它装置吸入,口服形式(液体或丸剂),可注射的,术中滴注或栓剂形式。
    • 20. 发明授权
    • Method of treating lung diseases with uridine 5′-diphosphate and analogs thereof
    • 用尿苷5'-二磷酸治疗肺部疾病的方法及其类似物
    • US06451288B1
    • 2002-09-17
    • US09645161
    • 2000-08-24
    • Richard C. Boucher, Jr.Sammy Ray ShaverWilliam PendergastBenjamin YerxaJanet L. RideoutRobert DoughertyDallas Croom
    • Richard C. Boucher, Jr.Sammy Ray ShaverWilliam PendergastBenjamin YerxaJanet L. RideoutRobert DoughertyDallas Croom
    • A61K912
    • A61K31/7068A61K9/0073A61K31/7072A61K45/06C07H19/10Y10S514/826Y10S514/851A61K2300/00
    • Compounds of Formula I: wherein: X1, and X2 are each independently either O− or S−; X3 and X4 are each independently either —H or —OH, with the proviso that X3 and X4 are not simultaneously —H; R1 is selected from the group consisting of O, imido, methylene and dihalomethylene; R2 is selected from the group consisting of H, halo, alkyl, substituted alkyl, alkoxyl, nitro and azido; R3 is selected from the group consisting of H, alkyl, acyl, aryl, and arylalkyl; and R4 is selected from the group consisting of —OR′, —SR′, —NR′, and —NR′R″, wherein R′ and R″ are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, alkoxyl, and aryloxyl, with the proviso that R′ is absent when R4 is double bonded from an oxygen or sulfur atom to the carbon at the 4-position of the pyrimidine ring, are used in methods of hydrating lung mucus secretions and treating lung disorders such as cystic fibrosis, ventilator-associated pneumonia, chronic bronchitis, chronic obstructive pulmonary disorder and primary ciliary dyskinesia. Pharmaceutical compositions containing compounds of Formula I, and novel compounds of Formula I are also described.
    • 式I化合物:其中:X 1和X 2各自独立地为O-或S-; X 3和X 4各自独立地为-H或-OH,条件是X 3和X 4不同时为-H; R 1为选自 由O,亚氨基,亚甲基和二卤代亚甲基组成的组; R 2选自H,卤素,烷基,取代的烷基,烷氧基,硝基和叠氮基; R 3选自H,烷基,酰基, 芳基和芳基烷基; 和R 4选自-OR',-SR',-NR'和-NR'R“,其中R'和R”独立地选自H,烷基,取代的烷基, 芳基,取代的芳基,芳基烷基,烷氧基和芳氧基,条件是当R4与氧或硫原子双键连接到嘧啶环的4位上的碳时,R'不存在,用于水合 肺粘液分泌物和治疗肺部疾病如囊性纤维化,呼吸机相关肺炎,慢性支气管炎,慢性阻塞性肺病和原发性纤毛运动障碍。 还描述了含有式I化合物和式I的新化合物的药物组合物。